(Q44994945)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20535513%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

title

Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20535513%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20535513%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

G Borriello

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20535513%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

F Fubelli

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20535513%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

F Marinelli

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20535513%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Carlo Pozzilli

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20535513%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

publication date

1 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20535513%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

published in

Neurological Sciences

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20535513%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

31 Suppl 3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20535513%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

303-307

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20535513%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10072-010-0348-8

5 February 2020

exact match

0 references

cites work

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0348-8

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0348-8

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0348-8

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0348-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0348-8

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0348-8

Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0348-8

Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0348-8

Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0348-8

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0348-8

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0348-8

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0348-8

The pharmacovigilance program on natalizumab in Italy: 2 years of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0348-8

New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20535513

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20535513

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20535513

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10072-010-0348-8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20535513%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference